Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001348362-25-000007
Filing Date
2025-05-16
Accepted
2025-05-16 16:51:22
Documents
1
Period of Report
2025-05-15

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 5175
  Complete submission text file 0001348362-25-000007.txt   6750
Mailing Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7
Business Address 100 - 740 MCCURDY ROAD KELOWNA A1 V1X 2P7 250-765-6424
Lexaria Bioscience Corp. (Issuer) CIK: 0001348362 (see all company filings)

EIN.: 202000871 | State of Incorp.: NV | Fiscal Year End: 0831
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 406 NATALIE LANE DANVILLE CA 94506
Business Address
Shankman Michael Elliot (Reporting) CIK: 0002035175 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39874 | Film No.: 25960138